DK1670903T3 - Behandling af neurodegenerative sygdomme - Google Patents

Behandling af neurodegenerative sygdomme

Info

Publication number
DK1670903T3
DK1670903T3 DK04764730T DK04764730T DK1670903T3 DK 1670903 T3 DK1670903 T3 DK 1670903T3 DK 04764730 T DK04764730 T DK 04764730T DK 04764730 T DK04764730 T DK 04764730T DK 1670903 T3 DK1670903 T3 DK 1670903T3
Authority
DK
Denmark
Prior art keywords
treatment
neurodegenerative diseases
fads2
medicament
inhibitors
Prior art date
Application number
DK04764730T
Other languages
English (en)
Inventor
Carsten Hopf
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/013980 external-priority patent/WO2005023858A1/en
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of DK1670903T3 publication Critical patent/DK1670903T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK04764730T 2003-09-05 2004-09-02 Behandling af neurodegenerative sygdomme DK1670903T3 (da)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP03019642 2003-09-05
PCT/EP2003/013980 WO2005023858A1 (en) 2003-09-05 2003-12-10 Protein complexes associated with app-processing
EP04001895 2004-01-29
EP04001894 2004-01-29
EP04007447 2004-03-26
EP2004004889 2004-05-07
EP2004004891 2004-05-07
EP04018874 2004-08-09
PCT/EP2004/009771 WO2005023833A2 (en) 2003-09-05 2004-09-02 Treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DK1670903T3 true DK1670903T3 (da) 2008-01-02

Family

ID=37035440

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04764730T DK1670903T3 (da) 2003-09-05 2004-09-02 Behandling af neurodegenerative sygdomme

Country Status (8)

Country Link
US (1) US20060216292A1 (da)
EP (1) EP1670903B1 (da)
AT (1) ATE371724T1 (da)
CA (1) CA2537844A1 (da)
DE (1) DE602004008658T2 (da)
DK (1) DK1670903T3 (da)
ES (1) ES2291917T3 (da)
WO (1) WO2005023833A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
AU2006259482A1 (en) * 2005-06-14 2006-12-28 Albert Einstein College Of Medicine Of Yeshiva University Effect of BRI proteins on abeta production
US20100077491A1 (en) * 2006-07-13 2010-03-25 Burnham Institute For Medical Research Modulators of RNF5 and Uses Thereof
US20100169988A1 (en) * 2006-12-06 2010-07-01 Bernhard Kohli Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
EP3225251B1 (en) * 2006-12-21 2020-02-12 H. Lundbeck A/S Modulation of activity of proneurotrophins
WO2008094663A2 (en) * 2007-01-31 2008-08-07 Adam Heller Electrochemical management of pain
CN102300582A (zh) 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
WO2012138284A1 (en) * 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
WO2012140148A2 (en) * 2011-04-12 2012-10-18 Universität Zürich Prorektorat Mnw Junction plakoglobin for diagnosis of cardiovascular diseases
KR101511737B1 (ko) * 2012-12-31 2015-04-20 대한민국 Sumo1 및 bace1의 결합 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물
EP3506927A4 (en) 2016-08-03 2020-05-06 University of South Florida REELIN COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASES
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
KR101873249B1 (ko) 2016-11-08 2018-07-05 대한민국 혈액기반 유전자 발현패턴을 이용한 치매 진단 방법
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
CN110144360B (zh) * 2019-06-06 2021-03-16 华中农业大学 一种二化螟SDR基因及其编码的蛋白质和应用、dsRNA及其扩增的引物对和应用
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN112641948A (zh) * 2020-12-25 2021-04-13 西北农林科技大学 靶基因SLC4A8在制备调控乳腺上皮细胞分泌β酪蛋白的药物的应用
CN116139277B (zh) * 2021-11-23 2025-06-24 中国科学院大连化学物理研究所 肝癌药物的辅助治疗药物及应用和治疗肝癌药物混合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) * 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
HU202728B (en) * 1988-01-14 1991-04-29 Eszakmagyar Vegyimuevek Synergetic fungicide and acaricide compositions containing two or three active components
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) * 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
EP1035207A1 (en) * 1999-03-09 2000-09-13 MultiGene Biotech GmbH cDNA molecules of the members of gene family encoding human fatty acid desaturases and their use in diagnosis and therapy
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
DE10000161A1 (de) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Verfahren zur Identifikation eines Proteaseinhibitors
AU2001237412A1 (en) * 2000-02-25 2001-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Presenilin deficient multipotent cell lines and screening methods for intramembrane regulated proteolytic activities using these lines
CA2301158A1 (en) * 2000-03-24 2001-09-24 Stephen J. Allen Screening methods for compounds useful for modulating lipid metabolism in disease

Also Published As

Publication number Publication date
CA2537844A1 (en) 2005-03-17
EP1670903A2 (en) 2006-06-21
EP1670903B1 (en) 2007-08-29
ATE371724T1 (de) 2007-09-15
WO2005023833A2 (en) 2005-03-17
DE602004008658T2 (de) 2008-06-12
ES2291917T3 (es) 2008-03-01
WO2005023833A3 (en) 2005-06-23
US20060216292A1 (en) 2006-09-28
DE602004008658D1 (de) 2007-10-11

Similar Documents

Publication Publication Date Title
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
EA200901373A1 (ru) Аминогетероциклические соединения
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
MA29870B1 (fr) Nouveaux dérivés de 1-azabicycloalkyles dans le traitement de troubles psychotiques et neurodégénératifs
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
SV2006002055A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
DK1778837T3 (da) Behandling af neurodegenerative sygdomme ved anvendelse af SCD4-inhibitorer
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
EA200700909A1 (ru) Азаиндолкарбоксамиды
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
EA200900261A1 (ru) Применение эсцина
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
DK1778623T3 (da) Derivater af 1-phenylalkancarboxylsyrer til behandling af neurodegenerative sygdomme
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DE602004010172D1 (de) Pharmazeutische zusammensetzungen zur behandlung von nierenfunktionsstörungen
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer